Hans Prenen
0000-0001-8802-7352
University Hospital Antwerp
11 papers found
Refreshing results…
Phase II study to determine the anti-tumor activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in esophageal cancer
Extensive CArdioVAscular Characterization and Follow-Up of Patients Receiving Immune Checkpoint Inhibitors: A Prospective Multicenter Study
Breast tumors interfere with endothelial TRAIL at the premetastatic niche to promote cancer cell seeding
Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer
eQTL Set–Based Association Analysis Identifies Novel Susceptibility Loci for Barrett Esophagus and Esophageal Adenocarcinoma
Immunoglobin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests
Macrophage miR-210 induction and metabolic reprogramming in response to pathogen interaction boost life-threatening inflammation
Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer
Specialized Blood Collection Tubes for Liquid Biopsy: Improving the Pre-analytical Conditions
RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment
Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy
Missing publications? Search for publications with a matching author name.